ES2170622A1 - Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. - Google Patents

Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.

Info

Publication number
ES2170622A1
ES2170622A1 ES009902673A ES9902673A ES2170622A1 ES 2170622 A1 ES2170622 A1 ES 2170622A1 ES 009902673 A ES009902673 A ES 009902673A ES 9902673 A ES9902673 A ES 9902673A ES 2170622 A1 ES2170622 A1 ES 2170622A1
Authority
ES
Spain
Prior art keywords
nucleic acid
infective
virus
directing
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009902673A
Other languages
English (en)
Other versions
ES2170622B1 (es
Inventor
Sanchez Luis Enjuanes
Toral Fernando Almazan
Martinez J Manuel Gonzalez
Permisan Ander Izeta
Zoltan Penzes
Villanueva Sara Alonso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8310818&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170622(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES009902673A priority Critical patent/ES2170622B1/es
Priority to DK00990628.0T priority patent/DK1234024T4/da
Priority to YUP-375/02A priority patent/RS50372B/sr
Priority to NZ518990A priority patent/NZ518990A/en
Priority to TR2004/01186T priority patent/TR200401186T4/xx
Priority to SI200030394T priority patent/SI1234024T2/sl
Priority to CZ20021882A priority patent/CZ302785B6/cs
Priority to CA002393325A priority patent/CA2393325A1/en
Priority to CNA2006100733455A priority patent/CN1872994A/zh
Priority to AU30051/01A priority patent/AU785081B2/en
Priority to ES00990628T priority patent/ES2218276T5/es
Priority to CNA2004100789786A priority patent/CN1616670A/zh
Priority to DE60010921T priority patent/DE60010921T3/de
Priority to AT00990628T priority patent/ATE267246T1/de
Priority to MXPA02005525A priority patent/MXPA02005525A/es
Priority to EP00990628A priority patent/EP1234024B2/en
Priority to PCT/EP2000/012063 priority patent/WO2001039797A2/en
Priority to PT00990628T priority patent/PT1234024E/pt
Priority to HU0203305A priority patent/HU228205B1/hu
Priority to CNB008165904A priority patent/CN100402643C/zh
Priority to PL356390A priority patent/PL206816B1/pl
Priority to IL14985900A priority patent/IL149859A0/xx
Priority to BR0016145-4A priority patent/BR0016145A/pt
Priority to EP04007406A priority patent/EP1437400A3/en
Priority to JP2001541529A priority patent/JP4637432B2/ja
Priority to SK761-2002A priority patent/SK7612002A3/sk
Priority to US10/148,669 priority patent/US7445928B2/en
Priority to KR1020027007118A priority patent/KR100755814B1/ko
Priority to ARP000106406A priority patent/AR027893A1/es
Priority to ZA200203560A priority patent/ZA200203560B/xx
Priority to NO20022419A priority patent/NO331812B1/no
Priority to IL149859A priority patent/IL149859A/en
Publication of ES2170622A1 publication Critical patent/ES2170622A1/es
Priority to US10/238,786 priority patent/US7368557B2/en
Publication of ES2170622B1 publication Critical patent/ES2170622B1/es
Application granted granted Critical
Priority to AU2006203327A priority patent/AU2006203327B2/en
Priority to US12/285,213 priority patent/US20100167352A1/en
Priority to US12/938,771 priority patent/US20110142879A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. El clon infectivo derivado de un coronavirus comprende un cDNA que codifica el gRMA de un coronavirus clonado bajo una secuencia promotora de la transcripción. El vector viral recombinante comprende un clon infectivo modificado para contener un ácido nucleico heterólogo insertado en dicho clon infectivo bajo condiciones que permiten la expresión de dicho ácido nucleico heterólogo. Los clones y vectores infectivos son útiles tanto en investigación básica como aplicada, en el desarrollo de sistemas de expresión eficientes de productos de interés (proteínas, enzimas, anticuerpos, etc.), vectores vacunales y terapia génica.
ES009902673A 1999-12-03 1999-12-03 Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. Expired - Fee Related ES2170622B1 (es)

Priority Applications (36)

Application Number Priority Date Filing Date Title
ES009902673A ES2170622B1 (es) 1999-12-03 1999-12-03 Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
IL14985900A IL149859A0 (en) 1999-12-03 2000-11-30 Infectious clones
MXPA02005525A MXPA02005525A (es) 1999-12-03 2000-11-30 Clones infecciosos.
NZ518990A NZ518990A (en) 1999-12-03 2000-11-30 Use of bacterial artificial chromosomes (BACs) to prepare heterologous DNA expression vectors to formulate vaccines
TR2004/01186T TR200401186T4 (tr) 1999-12-03 2000-11-30 Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
SI200030394T SI1234024T2 (sl) 1999-12-03 2000-11-30 Umetni kromosomi, ki vsebujejo sekvence nukleinskih kislin, sposobne usmerjanja tvorbe rekombinantnega rna virusa
CZ20021882A CZ302785B6 (cs) 1999-12-03 2000-11-30 Zpusob prípravy DNA odvozené od koronaviru, príslušné infekcní klony, vektory a vakcíny
CNB008165904A CN100402643C (zh) 1999-12-03 2000-11-30 感染性克隆
CNA2006100733455A CN1872994A (zh) 1999-12-03 2000-11-30 感染性克隆
AU30051/01A AU785081B2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant RNA-virus
ES00990628T ES2218276T5 (es) 1999-12-03 2000-11-30 Constructos de cromosomas artificiales que contienen secuencias de acidos nucleicos capaces de dirigir la formacion de un virus recombinante de arn.
CNA2004100789786A CN1616670A (zh) 1999-12-03 2000-11-30 感染性克隆
DE60010921T DE60010921T3 (de) 1999-12-03 2000-11-30 Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten
AT00990628T ATE267246T1 (de) 1999-12-03 2000-11-30 Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten
YUP-375/02A RS50372B (sr) 1999-12-03 2000-11-30 Infektivni klonovi
EP00990628A EP1234024B2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
PCT/EP2000/012063 WO2001039797A2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
PT00990628T PT1234024E (pt) 1999-12-03 2000-11-30 Construcoes de cromossomas artificiais contendo sequencias de acido nucleico capazes de dirigir a formacao de um virus de rna recombinante
DK00990628.0T DK1234024T4 (da) 1999-12-03 2000-11-30 Kunstige chromosomkonstruktioner, der indeholder nucleinsyresekvenser, som er i stand til at dirigere dannelsen af et rekombinant RNA-virus
CA002393325A CA2393325A1 (en) 1999-12-03 2000-11-30 Infectious clones
PL356390A PL206816B1 (pl) 1999-12-03 2000-11-30 Sposób otrzymywania DNA, klon zakaźny, E.coli, rekombinowany wektor wirusowy i szczepionka do ochrony zwierzęcia
HU0203305A HU228205B1 (en) 1999-12-03 2000-11-30 Infectious clones
BR0016145-4A BR0016145A (pt) 1999-12-03 2000-11-30 Clones infecciosos
EP04007406A EP1437400A3 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
JP2001541529A JP4637432B2 (ja) 1999-12-03 2000-11-30 感染性クローン
SK761-2002A SK7612002A3 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
US10/148,669 US7445928B2 (en) 1999-12-03 2000-11-30 Bacterial artificial chromosome construct encoding recombinant coronavirus
KR1020027007118A KR100755814B1 (ko) 1999-12-03 2000-11-30 감염성 클론
ARP000106406A AR027893A1 (es) 1999-12-03 2000-12-04 Clones infecciosos
ZA200203560A ZA200203560B (en) 1999-12-03 2002-05-06 Infectious clones.
NO20022419A NO331812B1 (no) 1999-12-03 2002-05-22 Fremgangsmate for a fremstille DNA avledet fra coronavirus samt infeksiose kloner, rekombinant viral vektor samt vaksine
IL149859A IL149859A (en) 1999-12-03 2002-05-27 Tribes of pollutants
US10/238,786 US7368557B2 (en) 1999-12-03 2002-09-11 Polynucleotides encoding porcine transmissible gastroenteritis virus
AU2006203327A AU2006203327B2 (en) 1999-12-03 2006-08-03 Infectious clones
US12/285,213 US20100167352A1 (en) 1999-12-03 2008-09-30 Infectious clones
US12/938,771 US20110142879A1 (en) 1999-12-03 2010-11-03 Infectious clones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009902673A ES2170622B1 (es) 1999-12-03 1999-12-03 Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.

Publications (2)

Publication Number Publication Date
ES2170622A1 true ES2170622A1 (es) 2002-08-01
ES2170622B1 ES2170622B1 (es) 2004-05-16

Family

ID=8310818

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009902673A Expired - Fee Related ES2170622B1 (es) 1999-12-03 1999-12-03 Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
ES00990628T Expired - Lifetime ES2218276T5 (es) 1999-12-03 2000-11-30 Constructos de cromosomas artificiales que contienen secuencias de acidos nucleicos capaces de dirigir la formacion de un virus recombinante de arn.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00990628T Expired - Lifetime ES2218276T5 (es) 1999-12-03 2000-11-30 Constructos de cromosomas artificiales que contienen secuencias de acidos nucleicos capaces de dirigir la formacion de un virus recombinante de arn.

Country Status (27)

Country Link
US (4) US7445928B2 (es)
EP (2) EP1437400A3 (es)
JP (1) JP4637432B2 (es)
KR (1) KR100755814B1 (es)
CN (3) CN1616670A (es)
AR (1) AR027893A1 (es)
AT (1) ATE267246T1 (es)
AU (2) AU785081B2 (es)
BR (1) BR0016145A (es)
CA (1) CA2393325A1 (es)
CZ (1) CZ302785B6 (es)
DE (1) DE60010921T3 (es)
DK (1) DK1234024T4 (es)
ES (2) ES2170622B1 (es)
HU (1) HU228205B1 (es)
IL (2) IL149859A0 (es)
MX (1) MXPA02005525A (es)
NO (1) NO331812B1 (es)
NZ (1) NZ518990A (es)
PL (1) PL206816B1 (es)
PT (1) PT1234024E (es)
RS (1) RS50372B (es)
SI (1) SI1234024T2 (es)
SK (1) SK7612002A3 (es)
TR (1) TR200401186T4 (es)
WO (1) WO2001039797A2 (es)
ZA (1) ZA200203560B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US7556957B2 (en) 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
JP4463481B2 (ja) * 2001-05-17 2010-05-19 ウニフェルシテイト ユトレヒト 機能的に欠失したゲノムを含むコロナウイルス様の粒子
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US7371837B2 (en) * 2004-07-21 2008-05-13 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
EP1619246A1 (en) * 2004-07-23 2006-01-25 Université de la Méditerranée, Aix-Marseille II RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening
EP1789566A1 (en) 2004-09-03 2007-05-30 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP1632247A1 (en) * 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
JP2007312649A (ja) * 2006-05-24 2007-12-06 Japan Health Science Foundation 再構築された感染性レトロウイルスゲノムクローンｄｎａ及びそれを含む微生物ならびにそれらの製造方法
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
FR2947839A1 (fr) * 2009-07-09 2011-01-14 Centre Nat Rech Scient Nouveaux agents antibacteriens
US9597390B2 (en) 2011-03-02 2017-03-21 Utrech University Infectious bronchitis virus (IBV) spike protein as subunit vaccine
GB201307528D0 (en) 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
AU2015259472A1 (en) * 2014-05-16 2016-11-10 Yale University Evolution of high-titer virus-like vesicles for vaccine applications
EP3143144A4 (en) * 2014-05-16 2017-12-20 Yale University VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION
ES2746150T3 (es) 2014-09-22 2020-03-04 Univ Minnesota Sistema de genética inversa para el virus Pichindé y métodos de uso
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CN107190022B (zh) * 2017-06-28 2020-10-30 浙江大学 一种快速构建禽传染性支气管炎病毒反向遗传株的方法
WO2019204654A1 (en) * 2018-04-18 2019-10-24 Utah State University Compositions and methods for zika virus characterization and vaccine development
KR102119875B1 (ko) * 2019-03-19 2020-06-05 한국화학연구원 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도
CN110468113A (zh) * 2019-08-07 2019-11-19 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组修饰的猪传染性胃肠炎病毒强毒株及其应用
CN110656120A (zh) * 2019-10-16 2020-01-07 中国医学科学院医学生物学研究所 一种乙脑病毒sa14-14-2的克隆方法及应用
CN111662885A (zh) * 2020-06-22 2020-09-15 扬州大学 两株基因组高度同源猪繁殖与呼吸综合征病毒强弱毒株感染性克隆构建、拯救与应用
CN112852873B (zh) * 2021-02-04 2023-03-24 华中农业大学 一种猪δ冠状病毒感染性克隆质粒的构建方法
CN115094142B (zh) * 2022-07-19 2024-05-28 中国医学科学院肿瘤医院 用于诊断肺肠型腺癌的甲基化标志物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1997034008A1 (es) * 1996-03-14 1997-09-18 Cyanamid Iberica, S.A. Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas
WO1999006582A1 (de) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Rekombinanter vektor, der infektiöse virale genomsequenzen mit einer grösse von mehr als 100 kb enthält, verfahren zu seiner herstellung und verwendung zur mutagenese der viralen sequenzen
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ES2026827A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5382425A (en) * 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
EP0683816B1 (en) * 1993-02-08 2000-11-02 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
WO1994029469A2 (en) * 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US20020146392A1 (en) 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995024929A2 (en) * 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
GB2289279B (en) * 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
AU4367096A (en) 1994-11-21 1996-06-17 Trustees Of Columbia University In The City Of New York, The Unique associated kaposi's sarcoma virus sequences and uses thereof
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US6287557B1 (en) 1995-02-21 2001-09-11 Cantab Pharmaceuticals Research Limited Methods of gene therapy using herpes viral vectors expressing GM-CSF
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US6133243A (en) 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
FR2751224B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6165493A (en) * 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
KR100879650B1 (ko) * 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스
AU770002B2 (en) * 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU778110B2 (en) 1999-12-14 2004-11-18 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
WO2001090340A2 (en) * 2000-05-21 2001-11-29 University Of North Carolina At Chapel Hill Assembly of large viral genomes and chromosomes from subclones
DE10044648A1 (de) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
JP4038127B2 (ja) * 2001-03-27 2008-01-23 ユニバーシティ オブ サスカチュワン サーコウイルスの培養方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1997034008A1 (es) * 1996-03-14 1997-09-18 Cyanamid Iberica, S.A. Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas
WO1999006582A1 (de) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Rekombinanter vektor, der infektiöse virale genomsequenzen mit einer grösse von mehr als 100 kb enthält, verfahren zu seiner herstellung und verwendung zur mutagenese der viralen sequenzen
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Also Published As

Publication number Publication date
WO2001039797A2 (en) 2001-06-07
SI1234024T1 (en) 2004-08-31
TR200401186T4 (tr) 2004-07-21
CZ302785B6 (cs) 2011-11-09
NO20022419L (no) 2002-07-30
AU3005101A (en) 2001-06-12
AU785081B2 (en) 2006-09-14
CN1872994A (zh) 2006-12-06
HUP0203305A2 (hu) 2003-01-28
EP1437400A3 (en) 2004-10-20
RS50372B (sr) 2009-11-10
CN1616670A (zh) 2005-05-18
DE60010921T3 (de) 2011-01-05
NO331812B1 (no) 2012-04-10
CN1402780A (zh) 2003-03-12
SK7612002A3 (en) 2002-11-06
KR100755814B1 (ko) 2007-09-07
AU2006203327A1 (en) 2006-08-31
AU2006203327B2 (en) 2009-09-10
PT1234024E (pt) 2004-08-31
WO2001039797A3 (en) 2002-01-24
KR20020060251A (ko) 2002-07-16
EP1234024A2 (en) 2002-08-28
ES2170622B1 (es) 2004-05-16
CZ20021882A3 (cs) 2002-11-13
EP1234024B2 (en) 2010-06-16
IL149859A (en) 2009-07-20
DE60010921D1 (de) 2004-06-24
ES2218276T3 (es) 2004-11-16
EP1437400A2 (en) 2004-07-14
NO20022419D0 (no) 2002-05-22
US20100167352A1 (en) 2010-07-01
IL149859A0 (en) 2002-11-10
CN100402643C (zh) 2008-07-16
JP2003515335A (ja) 2003-05-07
CA2393325A1 (en) 2001-06-07
YU37502A (sh) 2005-11-28
DK1234024T3 (da) 2004-09-13
SI1234024T2 (sl) 2010-10-29
US7368557B2 (en) 2008-05-06
DE60010921T2 (de) 2006-05-11
US7445928B2 (en) 2008-11-04
BR0016145A (pt) 2002-08-13
PL206816B1 (pl) 2010-09-30
MXPA02005525A (es) 2004-09-10
JP4637432B2 (ja) 2011-02-23
EP1234024B1 (en) 2004-05-19
ATE267246T1 (de) 2004-06-15
DK1234024T4 (da) 2010-10-11
ES2218276T5 (es) 2010-10-07
PL356390A1 (en) 2004-06-28
AR027893A1 (es) 2003-04-16
US20110142879A1 (en) 2011-06-16
HUP0203305A3 (en) 2004-07-28
HU228205B1 (en) 2013-01-28
NZ518990A (en) 2004-03-26
ZA200203560B (en) 2003-03-26
US20040086846A1 (en) 2004-05-06
US20030148325A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69942280D1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE341621T1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
ATE330007T1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
WO2002000711A3 (en) Ev-vegf nucleic acids and polypeptides and methods of use
PT1169442E (pt) Polipeptidos segregados e transmembranares e acidos nucleicos que os codificam
DK1246917T3 (da) Humane Stra6-polypeptider
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
ID27206A (id) Generasi produk-produk perbanyakan gena dari protein-protein fusi simerik melalui pemutusan endoprotease ubikuitus
DE60018601D1 (de) HBV/HCV Virus-ohnliche Particle
WO2000068376A8 (en) Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
DE69838097D1 (de) Infektiöser klon für menschlichen parainfluenzavirus-typ
EP1241186A3 (en) Human growth arrest specific gene 6 (gas-6) and nucleic acids encoding the same
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
DE69943058D1 (de) Loslösendes protein 5 - ucp5
EP1277833A3 (en) Costal-2 homologue
EP1241180A3 (en) Human A33 antigen-like protein and nucleic acids encoding it
ATE447614T1 (de) Menschliches suppressor von fused
DK1191101T3 (da) PRO241 polypeptider og nucleinsyre kodende herfor
DK1217006T3 (da) Polypeptider og nucleinsyrer kodende for samme

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020801

Kind code of ref document: A1

Effective date: 20020801

FG2A Definitive protection

Ref document number: 2170622B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180928